Exchange: NYSEArca·Updated 07:58 PM EST
XBI logo

XBI SPDR S&P Biotech ETF

$140.18
$3.94
(2.73%)
Today
Closed $140.18
$1.04
(0.74%)
After Hours
Vol9.44M
52W High$169.89
52W Low$117.11
69

Bullish Sentiment

How do you feel about XBI?

TradeSun
$XBI I think we’re getting closer to a buying window for small- and mid-cap biotech. Pull up the five-year charts on $ALT, $GPCR, $AUTL, and $CABA. Several of these names are trading near the bottom of their five-year ranges. September 21 is where the selloff starts to stand out to me. Treasury yields pushed higher in the days that followed. The 10-year hit its highest level since 2007, the 30-year reached levels last seen in 2004, and the 2-year climbed as well. I think this sector is due for a rebound at some point. Take a look at the charts.
23
RonIsWrong
$XBI Exclusive-US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
13
BiotechSwings
Thursday close and that morning pop did not stick imo $XBI closed 144.12, down 0.63% after tagging 148.93, still above its 200 day near 143.25 IBB closed 203.72, down 0.81%, large caps doing the holding work again $INSM closed 144.46, up 20.6% on the Sanofi takeover chatter, clear leader on the day $SLS closed 14.86, down 17.2% after the offering, and it is still up about 76% in five sessions after running to 24.89 Friday is the practical window now. $CAPR and Savara both sit on Nov 22 PDUFAs, Sunday dates, so tomorrow is the session that matters
10
BigGainTom
$XBI looks like jensen ended the AI rally with his behavior. Should help biotechs like $AQST and $IOVA.
11
lonelywarrior
$XBI - $URGN, $TVTX, $RARE holding nice today because fundamentals, revenue and FDA-approved products matter.
8
BiotechSwings
Thursday morning and biotech is not giving the bid back $XBI closed Wednesday at 145.04, down 0.17%, still under the 50 day at 153.28 but holding above the 200 day at 143.25. $IBB closed at 205.39, down 0.76%, under its 50 day at 208.86 and well above its 200 day at 187.32 premarket both are ticking up about 0.65%, $XBI near 145.99 and $IBB near 206.72. picky regime, not broken imo $SLS is the premarket story again. down about 20% near 14.45 after pricing that $150M offering at 13.00, and people keep skipping why the money showed up. REGAL met its endpoint, median survival 24.0 months vs 14.7, hazard ratio 0.59. funded after a Phase 3 win, with a BLA planned for the first half of 2027
7
BiotechSwings
Sunday night and I'm mostly in cash, and I'm fine with it $XBI closed Friday at 140.18, down 2.73%, under its 50 day at 152.71 and under its 200 day at 143.36, down 7.29% in five sessions that's not a chase regime imo. cash lets me act when a real setup shows up instead of forcing one that isn't there
4
LabPsycho
$XBI My model suggestiong a capitulation event before year end. I expect many biotechs, esp. the ones that have drifted down most of the year to snowball and give up another 30-40% before year end. There may be a January - Feb bounce effect for about 3 out of 70 where one could potentially make 300% but the odds of picking one of those 3 very small.
1
3
CH_Expat
$XBI Serious question: How can all bios I like be around 52W-Low while XBI did okay in that period?
6
JFais
General rule of thumb: Companies dedicate more slides to a program with each update= a good sign (Converse is true as well) $XBI *No-brainer I know, but still worth reiterating
1
1
DavyDaveCharts
$XBI multiple taps of the trend line. Currently facing a 50-61.8 fib retracement zone. Rejection here raises the risk of a trend line breach.
4
chessNwine
$XBI Weekly. Two weeks since last chart update, bios flirting with major head & shoulders top breakdown. $144 key level. Many growth managers in both AI & bios = source of liquidity risk
3
RonIsWrong
$XBI Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
3
JFais
Late-stage clinical = clear path to market (no science projects) $XBI Opportunity to enter before they get recognized as growth stocks
3
MarkM
$XBI I don't think it does. Rather, a risk of imminent rate hikes is the spooky character. CPI this week was hotter than forecast; with tomorrow's PPI likely to confirm. And two Fed Presidents just today reiterated there may be a need for rate hikes in order to get inflation under control in the near term (from Google AI): "Yes, two regional Federal Reserve Bank Presidents—Beth Hammack of Cleveland and Mary Daly of San Francisco—spoke about interest rates today, Thursday, November 12, 2026. Both indicated that further rate hikes are likely needed to cool inflation, though they favored a gradual pace over aggressive increases."
3
The_Joker_has_Spoken
$XBI $LABD $LABU Open Interest by Strike for next weeks OPEX Puts out number Calls more than 2.5 to 1
3
LabPsycho
$XBI Entering phase 2, rate of-d$/dt of the decline increasing, augmented by normal or increasing trading volume not a good harbinger - slipping on the precipice, heading towards cliff IMO
2
RotationReport
$XBI getting close to that top breakdown. I guess $ANT is just going to kill us now and pass on the curing cancer
2
gerrypicker
$XBI Very well-defined bearish Head & Shoulders pattern on the daily chart, starting June 2026. Also, a break below the 200 DMA (about 143) could see more downside. Support looks to be 138. I'm holding at the moment.
2
JFais
Q: Are you currently leaning to commercial names or late-stage setups here for new entries? $XBI A: Commercial is first choice, but no preference (all about where r/r most attractive, as much derisking as possible so I can sleep well at night). I am as boring as they come :)
2

Advertisement|Remove ads.